Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).
Nur Aisyah ZainordinSharifah Faradilla Wan Muhamad HattaFatimah Zaherah Mohamed ShahThuhairah Abdul RahmanNurhuda IsmailZaliha IsmailRohana Abdul GhaniPublished in: Journal of the Endocrine Society (2019)
A 12-week therapy with dapagliflozin, in addition to insulin and metformin therapies, in high-risk patients resulted in significant reductions in HbA1c, FBG, and surrogate markers of the endothelial function. Although the dapagliflozin group demonstrated a significant association between reduction in HbA1c and improvement in FMD, there was no significant difference in FMD between the 2 groups.